Search
Ibrutinib
go.drugbank.com/drugs/DB09053ApprovedInvestigationalApril 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. … [L12228] Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.[L43020]
Valsartan
go.drugbank.com/drugs/DB00177ApprovedInvestigational[A174124,A173869] Valsartan was initially approved in 1996 in Europe for the treatment of hypertension in adults. Shortly after, in 1997, this drug was approved in the United States. … Valsartan is commonly used for the management of hypertension, heart failure, and Type 2 Diabetes-associated nephropathy, particularly in patients who are unable to tolerate ACE inhibitors.
Mixtures: VALSARTAN HCT MK 80 MG/12.5 MG COMPRIMIDOS RECUBIERTOSCategories: Antihypertensive Agents Indicated for HypertensionEfavirenz
go.drugbank.com/drugs/DB00625ApprovedInvestigationala high risk for HIV transmission. … For HIV infection that has not previously been treated, efavirenz and lamivudine in combination with zidovudine or tenofovir is the preferred NNRTI-based regimen.
Categories: Antivirals for Systemic Use, Antiinfectives for Systemic UseProducts: EFAVAX ® TABLETAS RECUBIERTAS POR 600MGCopper histidinate
go.drugbank.com/drugs/DB32041ApprovedIt was approved by the US FDA in January 2026 for the treatment of pediatric patients with Menkes disease.[L54993,L54998] … [A275383] Copper histidinate is a subcutaneously-administered copper-histidine complex that allows for copper supplementation in patients with defective ATP7A transporters.
Sotorasib
go.drugbank.com/drugs/DB15569ApprovedInvestigational[A187547] The drug [MRTX849] is also currently being developed and has the same target. … [L34288] This mutation makes up >50% of all KRAS mutations.[A187550] Mutant KRAS discovered in 1982 but was not considered a druggable target until the mid-2010s.
Sebelipase alfa
go.drugbank.com/drugs/DB11563ApprovedInvestigational[L39337] Sebelipase alfa is a recombinant form LAL approved for the treatment of LAL deficiency. … This lipid accumulation can lead to end-organ damage in the form of liver dysfunction or malabsorption secondary to intestinal dysfunction.
Esmolol
go.drugbank.com/drugs/DB00187ApprovedInvestigationalWithdrawnOther esmolol formulations are still available for use.[L43942] … The FDA withdrew its approval for the use of all parenteral dosage form drug products containing esmolol hydrochloride that supply 250 milligrams/milliliter of concentrated esmolol per 10-milliliter ampule
Categories: Antihypertensive Agents Indicated for HypertensionPariglasgene brecaparvovec
go.drugbank.com/drugs/DB16801Approved[L64050] The FDA granted pariglasgene brecaparvovec-opnr accelerated approval on August 19, 2026, making it the first approved treatment for glycogen storage disease type Ia. … Pariglasgene brecaparvovec-opnr is an adeno-associated virus serotype 8 (AAV8)–based gene therapy for glycogen storage disease type Ia (GSDIa), a disorder caused by deficiency of the enzyme glucose-6-phosphatase
Synonyms: Recombinant adeno-associated virus serotype 8 vector encoding human glucose-6-phosphatase-alpha (G6Pase or G6PC)Saquinavir
go.drugbank.com/drugs/DB01232ApprovedInvestigationalSaquinavir is an HIV-1 protease inhibitor used in combination with [ritonavir] and other antiretrovirals for the treatment of human immunodeficiency virus-1 (HIV-1) infection.
Categories: Antivirals for Systemic Use, Antiinfectives for Systemic UseQuaternium-15
go.drugbank.com/drugs/DB14198ApprovedQuaternium-15 is a quaternary ammonium salt used as a surfactant and preservative in many products including cosmetics.